Every intervention Outliyr has scored for longevity, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for longevity; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
84 of 147 evaluated interventions score 3.0+ out of 10 for longevity · 28 comparisons
Longevity is broad enough that "best for X" usually loses the plot. This list is ranked by each report's longevity-specific subrating, not by its overall BioHarmony score, so a genuinely elite general intervention can sit below a narrower one built for this goal specifically. Read the note under a row before assuming a higher spot means a better product across the board.
This hub covers single, individually scored interventions with a real longevity mechanism, not whole-body stacks, general wellness routines, or anything still awaiting a full BioHarmony write-up. A high position here reflects evidence quality and effect size specific to lifespan and healthspan outcomes, not affordability, ease of use, or how well-known the intervention is.
The existing rationale points to this narrower claim: this verified source followed 55,137 adults and found leisure-time running associated with lower all-cause and cardiovascular mortality. This supports aerobic training for. That does…
Zone 2 cardio tops this list because its longevity subrating (8.0–8.5/10) sits alongside genuinely elite general evidence (Strong recommend overall). Steady sub-threshold aerobic work is one of the few interventions here with both mechanistic plausibility (mitochondrial biogenesis, VO2max) and a large observational mortality literature behind it.
Kumar 2023 anchors the most relevant signal. Glycine fits longevity because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Glycine ties for the top longevity subrating (8.0–8.5/10) on the strength of its role in glutathione synthesis and collagen turnover, two pathways that decline with age. It's cheap, well tolerated, and rated Strong recommend overall, which is part of why it ranks this high despite not being a headline longevity compound.
The signal is dose-dependent across frequency and session duration, and the cohort followed men for two decades, which is unusually long for any intervention. The honest caveat is residual confounding: healthier, wealthier,…
Traditional Finnish sauna matches the top longevity subrating (8.0–8.5/10) on repeated-exposure cardiovascular mortality data, the same literature that anchors its Strong recommend overall rating. It ranks just above infrared sauna here because the dry-heat protocol has the deeper longevity-specific evidence, not because infrared is a weaker sauna.
Harrison 2009 anchors the most relevant signal. Rapamycin fits longevity when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints remain…
Rapamycin ties for the highest longevity subrating on this list (8.0–8.5/10) even though its overall rating is Worth trying, a step below the tier the three interventions above it carry. That gap is intentional: rapamycin's mTOR-inhibition evidence is genuinely strong for lifespan extension specifically, but its side-effect and monitoring burden pulls the overall score down in a way that has nothing to do with this goal.
Singh 2023 reports Flagship aging paper; taurine declines with age and supplementation improved lifespan or healthspan markers in non-human models. The score stays conditional because Taurine still needs better outcome data for…
Taurine actually carries a higher overall rating (Strong recommend) than glycine and traditional sauna above it, but its longevity subrating (7.5–8.0/10) is a step behind theirs, which is why it sits at position five instead of higher. The evidence for taurine's role in age-related decline is real, just not as longevity-specific as the two rows above it.
Kihara 2002 supports the strongest part of the claim. The existing rationale points to this narrower claim: Longevity signal comes mainly from traditional Finnish sauna observational data, especially this verified source, plus…
Infrared sauna shares taurine's longevity subrating (7.5–8.0/10) and draws on much of the same heat-stress cardiovascular literature as its traditional counterpart, though with less direct mortality data of its own. There's a roundup of tested home units linked below.
The protocol raises VO2max, a major marker of cardiorespiratory reserve. The original study reported about a 7% VO2max improvement after six weeks Helgerud 2007, while a broader umbrella review found that high-intensity…
Norwegian 4x4 interval training carries the highest overall rating of anything in this top eight (Strong recommend), yet it sits at position seven because its longevity subrating (7.5–8.0/10) is a step behind the sauna and cardio protocols above it. The VO2max gains are exceptional; the longevity-specific literature is simply thinner than zone 2's.
Kiechl 2018 anchors the strongest signal. The existing rationale points to this narrower claim: this verified source is the strongest human signal, with 20-year dietary follow-up linking higher spermidine intake to lower…
Spermidine closes out the top eight on autophagy-linked evidence, with a longevity subrating (7.5–8.0/10) that tracks closely with its Strong recommend overall rating. There's a supplement roundup linked below if you want to compare tested brands.
Red Light Therapy targets mitochondrial and inflammatory biology, with Hamblin 2017 supporting anti-inflammatory mechanisms. The case is healthspan-adjacent rather than lifespan-proven. No human trial shows Red Light Therapy extends life. The strongest…
Jolliffe 2021 anchors the most relevant signal. Vitamin D3 + K2 fits longevity when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are present. The score stays bounded because benefits are…
The existing rationale points to this narrower claim: this verified source reported lifespan extension in aged mice, while this verified source supports a C. elegans longevity mechanism. Human lifespan data. That does…
Lincoff 2023 and Perkovic 2024 moved event risks that can affect lifespan in high-risk groups. The longevity case is therefore conditional, not universal. If obesity, diabetes, CVD, CKD, or MASH are shortening…
Grosso 2017 pooled 22 prospective studies and found high total-flavonoid intake associated with 26 percent lower all-cause mortality (RR 0.74), with flavonols especially strong (HR 0.64). These are associations, not proof of…
Yousefzadeh 2018 supports fisetin lifespan and healthspan effects in mice; Farr 2024 tempers human extrapolation for D+Q. The score stays bounded because Senolytics evidence for longevity can depend on age, disease context,…
Longevity relevance is indirect: maintaining attention, sleep, emotional regulation, and cognitive flexibility protects functional aging. Neurofeedback does not have lifespan, epigenetic-age, or disease-incidence trials. The score is preserved because durable cognitive self-regulation…
Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide…
The v0 longevity score is preserved but explicitly bounded: Pickart 2014 and Pickart 2018 describe broad gene-expression effects, but no human lifespan, healthspan, or systemic injection RCT validates a longevity outcome. The…
Walking volume is one of the most robustly mortality-linked behaviors measured: across 47,471 adults the most active step quartile had a 53 percent lower all-cause death rate (Paluch 2022). Higher cardiorespiratory fitness,…
Whole-Body Vibration may influence longevity indirectly by mitigating sarcopenia, improving balance, and reducing fall risk, pathways linked to mortality in aging populations. Systematic reviews report mixed effects on muscle loss in seniors,…
The evidence points to a plausible use case without proving a universal response. Al-dulaimi et al. 2025 is the best anchor here because it reports independent in vitro study and normal epithelial…
The mechanism is VO2max, a major marker of cardiorespiratory reserve that tracks tightly with survival in Mandsager 2018, where elite fitness was associated with about 80 percent lower all-cause mortality versus low…
Evidence from the SURMOUNT-1 extension shows tirzepatide reduced progression to type 2 diabetes, a key longevity factor (Jastreboff 2025). Tirzepatide also improves cardiometabolic risk markers such as weight, blood pressure, and lipid…
The evidence points to a plausible use case without proving a universal response. Chen X et al. 2026 is the best anchor here because it reports 41 randomized trials, 2,287 participants and…
The rationale for Metformin and longevity rests on a few epidemiologic studies that note lower mortality among diabetic patients taking the drug, and on the TAME trial design that aims to test…
Longevity is speculative. Tissue repair, inflammation resolution, and injury resilience plausibly support healthspan, but no lifespan or age-related disease trial exists. The score remains moderate because chronic peptide use adds unresolved safety…
Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits longevity when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is…
HRV is an observational mortality marker, but changing HRV with tVNS has not been shown to extend lifespan or reduce mortality in healthy adults. The score stays bounded because Vagus Nerve Stimulation…
In Alehagen 2013 (KiSel-10), 200 mg CoQ10 plus 200 micrograms selenium daily in elderly Swedes cut cardiovascular mortality from 12.6% to 5.9% over roughly five years, a striking outcome that persisted at…
Beelman 2020 argues ergothioneine is a longevity vitamin under-supplied by the American diet, building on Bruce Ames's triage theory in Ames 2018. Blood levels decline after age 60 and low levels track…
Rothenberg 2025 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Longevity rationale is mitochondrial and preclinical, with no human lifespan or validated aging-biomarker RCT. this verified…
Longevity claims are indirect and should stay modest. Lower pain, better mobility, and improved recovery can support healthspan behavior, but there are no human lifespan trials. The longevity rationale is far weaker…
GlyNAC is one of the few supplements with human data on multiple hallmarks of aging, not just a surrogate marker. Kumar 2023 reported improvement in several aging hallmarks including mitochondrial dysfunction, inflammation,…
Zhang 2024 anchors the most relevant signal. NMN fits longevity when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more…
High-Dose Melatonin has a longevity story but not a longevity trial base. The mechanisms overlap with oxidative stress, mitochondrial function, immune aging, and cellular maintenance, yet no verified human study shows lifespan…
Higher HRV is a solid longevity biomarker; HRV-BF directly improves this marker. Mechanism strong, direct mortality endpoints absent. The score stays bounded because HRV Biofeedback evidence for longevity can depend on breathing…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Maleki-Hajiagha 2024 points in the same direction, but route, dose,…
Ryu 2016 found lifespan extension in C. elegans and improved muscle function in rodents. Human lifespan evidence does not exist. That makes Urolithin A more defensible when longevity is a real bottleneck…
Brown seaweed is a documented staple of the traditional Okinawan diet, one of the world's longest-lived populations, as detailed by Willcox 2014. That makes fucoidan a plausible contributor to a longevity-supportive dietary…
Dollerup 2018 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: NAD+ decline is an established aging biology theme, and the NRK pathway is well-characterized, but no…
The evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary…
Hachmo 2020 should be treated as hypothesis-generating because of methodological critique and financial conflicts. No authority body endorses HBOT as an anti-aging intervention.
Chronic mTORC1 activation remains the main longevity tension. The Vangipurapu 2019 Finnish cohort linked several amino acids with worse glucose and insulin-secretion patterns, though this is observational and not an EAA supplement…
Adequate intake is clearly necessary for health, and severe deficiency is fatal, but the leap from adequacy to extended lifespan is not supported by human outcome data. Large antioxidant-supplement prevention trials have…
Longevity claims remain capped by missing hard-outcome trials. Mechanisms such as lower insulin, mTOR suppression, AMPK activation, and BHB signaling are interesting, but human lifespan or MACE RCTs do not exist. Iatan…
Glutathione decline tracks aging, and the GlyNAC work from the Sekhar group reported reversal of several aging hallmarks in older adults, but that is glycine plus N-acetylcysteine and comes from one small…
J-147 reduced age-associated transcriptional drift in aged mouse brains and extended median lifespan in fruit flies (Goldberg et al. 2018). It targets a real longevity pathway, but no mammalian lifespan or human…
TRT has no proven longevity benefit. TestES 2024 found short-to-medium-term safety reassurance but mortality evidence remained sparse, so TRT should not be sold as a lifespan intervention.
Exercise mimetics are theoretically longevity-relevant, but SLU-PP-332 has no lifespan data. Any longevity framing should be limited to pathway-level inference from ERR energy-homeostasis biology described by Giguere 2008.
Human longevity evidence rests on senolytic class pilots. Hickson 2019 reduced senescence markers in 11 days. Justice 2019 showed feasibility and physical function improvement in IPF. The bone trial Farr 2024 was…
BFR supports longevity-adjacent muscle-preservation pathways, but no direct lifespan or hard healthspan trials exist.
Longevity interest comes mostly from the glycine-plus-NAC (GlyNAC) glutathione-restoration work in older adults; standalone NAC has no human lifespan data. See /reports/glynac/ for the combination.
Indirect only. Cardiometabolic risk-factor improvement is consistent with healthier aging, but there are no human lifespan or hard-outcome trials for spirulina.
Traditional Rasayana use, antioxidant effects, bone preservation, and hormone support fit a healthspan story. No human lifespan or hard aging-outcome data exist.
Longevity remains indirect. Rasayana use in Ayurveda, stress reduction, sleep support, and inflammatory modulation all point in a healthspan-friendly direction, but there are no human lifespan trials. The practical longevity case is…
Longevity claims are not proven. Cochrane 2020 found little or no effect on all-cause mortality despite large trial volume.
Fuku 2015 associated a MOTS-c polymorphism with exceptional longevity in Japanese centenarians, and endogenous levels relate to aging biology. No lifespan-extension study from exogenous MOTS-c exists.
Longevity scoring remains cautious because GH/IGF-1 biology cuts both ways: metabolic improvements may help high-VAT adults, while higher IGF-1 can raise theoretical cancer-growth concern in susceptible users.
Longevity is the most eye-catching claim and the weakest-supported. The flagship 266-person elderly cohort reported mortality falling roughly 2 to 4 fold over 6 years, per Khavinson 2003. That is an extraordinary…
Mao 2012 reported that pine pollen improved memory, lowered inflammatory cytokines, and delayed fibroblast senescence in a D-galactose mouse aging model. That is a reasonable anti-aging signal, and TCM positions pine pollen…
No longevity or lifespan data exists for Tβ4 in any species. The peptide is studied as a tissue-repair agent, not a longevity intervention; the antifibrotic Ac-SDKP arm is mechanistically interesting for aging…
Tissue repair and cytoprotection; no lifespan studies. Maintenance use for longevity is community practice without trial support.
Glycine and connective-tissue maintenance fit healthspan logic, but collagen peptides have no human lifespan or mortality trials. Longevity claims should stay conservative.
Muscle preservation tracks with longevity, but WB-EMS has no lifespan or mortality trials. This is a muscle-maintenance proxy score, strongest when EMS helps someone train who otherwise would not.
Longevity evidence is mechanistic and indirect through mood, sleep, metabolic markers, and retinal preservation; saffron has no human lifespan, mortality, or aging-clock endpoint.
Neuroprotection is longevity-adjacent, but Semax has no lifespan, all-cause mortality, dementia-prevention, or long-term healthspan trial.
The nutrient density and modest cardiometabolic effects are longevity-adjacent, but there is no human lifespan or healthspan outcome evidence for chlorella, so this is mechanistic optimism, not data.
The longevity use case is the original resveratrol story and the weakest clinical reason to supplement. Pacholec 2010 found resveratrol was not a direct SIRT1 activator under native-substrate assays, and Mansouri 2025…
AMPK, mTOR, glucose, inflammation, and microbiome mechanisms are longevity-adjacent, but there is no human lifespan data. Berberine is better seen as metabolic risk management in selected users than a broad longevity supplement.
No human longevity data. Mechanistic and animal signals only. The marketing outruns the evidence here.
Chronic dehydration and extreme sodium patterns track with risk, but ordinary supplementation is preventive support rather than a longevity intervention.
Longevity support is indirect through neuroprotection, gut, immune, and inflammation pathways. No lifespan RCT, human cohort, or validated aging-biomarker trial supports a high score.
Membrane integrity and cortisol regulation are aging-relevant, but no lifespan, mortality, or long-term disease-prevention RCTs support PS as a longevity intervention.
No longevity endpoint data exist. The mechanism is functional and short-lived, not a durable aging-pathway intervention.
Animal lifespan data on ketogenic states exist, but there is no human longevity evidence for exogenous ketones, and the acute-only pharmacology makes a durable aging effect unlikely from intermittent dosing.
No human longevity or healthspan endpoint has been tested. The pitch rests on historical mystique, not outcome data.
CD38 inhibition is the primary longevity claim. Escande 2013 showed apigenin inhibited CD38 and increased NAD+ in cells and mice. No human trial confirms NAD+ elevation, healthspan benefit, or longevity-relevant outcomes at…
Retatrutide has no lifespan or long-term disease-outcome evidence. Treating it as a longevity intervention in healthy adults overreaches the data and ignores the FDA and authority gaps documented in the audit.
Chronic IGF-1 elevation has epidemiological cancer-risk associations, including Endogenous Hormones Collaborative Group 2010. Longevity trade-off is negative to neutral.
Longevity is humanin's most interesting and most cited use case, yet it stays modest because the human evidence is correlational, not interventional. Children of centenarians carry much higher circulating humanin, the peptide…
Traditional longevity tonics with antioxidant and immune mechanisms, but no human lifespan or healthspan outcome data. Mechanism-only.
Mild mitochondrial uncoupling is a long-standing longevity hypothesis, and BAM15 improved several aging-relevant endpoints in mice, but no lifespan study exists for it in any species.
Longevity is the central pitch because NAD+ declines with age, per Massudi 2012, and restoring it is a major aging hypothesis, per Rajman 2018. But no human longevity or healthspan trial exists…
No human longevity trial has tested C15:0 supplementation against mortality, frailty, biological-age clocks, telomeres, or healthspan endpoints. Ciesielski 2024 (Ciesielski 2024) frames essentiality as controversial rather than settled. The longevity pitch is…
C60 longevity remains weak because Baati 2012 is small animal evidence and Shytikov 2021 found C60 similar to water controls, not a clean lifespan extension. The 2024 to 2026 audit found no…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 27 of 84 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Taurine | $3–$10 | 1-3 g, 30-60 minutes before sleep | Over the counter |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Vitamin D3 + K2 | Not priced yet | ||
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Polyphenols (Dietary) | Not priced yet | ||
| Senolytics | Not priced yet | ||
| Neurofeedback | Not priced yet | ||
| Molecular Hydrogen | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Rucking (Weighted Walking) | Not priced yet | ||
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Epitalon | $95–$1,100 | 5-10 mg/day subcutaneous | Grey market |
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Time-Restricted Eating | Not priced yet | ||
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Ergothioneine | Not priced yet | ||
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| PEMF (Pulsed Electromagnetic Field Therapy) | $3–$117 | 20-30 min mat session | Over the counter |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| High-Dose Melatonin | Not priced yet | ||
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Astaxanthin | Not priced yet | ||
| Urolithin A | $50–$100 | 500 mg/day | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Essential Amino Acids | Not priced yet | ||
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| J-147 | Not priced yet | ||
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| MOTS-c | $100–$200 | 5-10 mg SC | Research use only |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Thymalin | $113–$590 | 5 to 10 mg | Grey market |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Collagen Peptides | $8–$40 | 2.5-10 g hydrolyzed collagen peptides | Over the counter |
| Full-Body EMS | Not priced yet | ||
| Saffron | Not priced yet | ||
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| Resveratrol | Not priced yet | ||
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| Electrolytes | Not priced yet | ||
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| Apigenin | $15–$35 | 25-50 mg pure apigenin 30-60 min before bed | Over the counter |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| CJC-1295 | $80–$200 | 1-2 mg subcutaneous | Grey market |
| Humanin | $100–$300 | 1 mg subcutaneous, twice weekly | Research use only |
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
| BAM15 | Not priced yet | ||
| NAD+ (Direct) | $300–$1,600 | 250 to 750 mg | In clinic |
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
| C60 (Buckminsterfullerene) | Not priced yet |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live body-composition subrating, not the overall BioHarmony score, since body composition is the goal this category is built around. Tirzepatide leads both measures.…
This page ranks by the live endurance-cardio subrating, not by BioHarmony overall, and the order flips. SLU-PP-332 leads at 6.5–7.0/10 despite carrying the lowest overall score on the…
GHK-Cu wins this on evidence. It has human wound and skin data behind it. AHK-Cu has one unreplicated dish study and no human trial at all. Use GHK-Cu…
Neither, if fat loss is the goal. Both score 2.0–2.5/10 on body composition, which is the row a vendor sells them on. AOD-9604 scores 3.0–3.5/10 overall and its…
Melatonin, dosed low. It scores 7.5–8.0/10 against apigenin's 5.5–6.0/10 and wins the sleep rows outright. The morning hangover apigenin markets against comes from taking too much, not from…
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0–9.5/10 against KPV's 7.0–7.5/10 and wins nearly every other row, because it…
Bromantane, for anything you plan to repeat. It scores 7.0–7.5/10 against phenylpiracetam's 5.5–6.0/10 and wins every shared use case that is not a floor tie: energy 6.2/10 to…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
CoQ10 scores 7.0–7.5/10 and methylene blue 6.0–6.5/10, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
The scores tie at 6.0–6.5/10 and 6.0–6.5/10 and every shared subrating sits within half a point, so the numbers decide nothing. Access and evidence decide it. Gonadorelin is…
Zone 2 Cardio, at 8.0–8.5 out of 10 for longevity. The existing rationale points to this narrower claim: this verified source followed 55,137 adults and found leisure-time running associated with lower all-cause and cardiovascular mortality.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 8.0–8.5 out of 10 for longevity.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for longevity but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
84 of the 147 interventions evaluated for longevity score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
